StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report issued on Saturday.

• Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

XENE has been the subject of several other reports. Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating and a $67.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $57.38.

Check Out Our Latest Research Report on Xenon Pharmaceuticals

Xenon Pharmaceuticals Price Performance

XENE stock opened at $34.26 on Friday. The company has a market capitalization of $2.62 billion, a PE ratio of -12.15 and a beta of 1.26. The firm's 50-day moving average is $37.72 and its 200 day moving average is $39.73. Xenon Pharmaceuticals has a 12 month low of $33.27 and a 12 month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.05. Sell-side analysts forecast that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Insider Activity

In related news, CEO Ian Mortimer sold 16,315 shares of the business's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.52% of the company's stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock valued at $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Barclays PLC increased its stake in Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock worth $590,000 after purchasing an additional 13,903 shares during the period. Walleye Capital LLC purchased a new position in Xenon Pharmaceuticals in the 3rd quarter valued at approximately $4,132,000. Assenagon Asset Management S.A. grew its stake in Xenon Pharmaceuticals by 12.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company's stock worth $9,350,000 after purchasing an additional 26,235 shares in the last quarter. Finally, State Street Corp grew its position in shares of Xenon Pharmaceuticals by 13.2% during the third quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock worth $11,004,000 after buying an additional 32,701 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

Featured Articles

• Five stocks we like better than Xenon Pharmaceuticals
• Low PE Growth Stocks: Unlocking Investment Opportunities
• Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
• What is the Dow Jones Industrial Average (DJIA)?
• JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?
• What is the NASDAQ Stock Exchange?
• Buy the Chewy Stock Reversal? Here’s Why Now Is the Time

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?

Before you consider Xenon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.

While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here